Idarubicin and standard-dose cytosine arabinoside in adults with recurrent and refractory acute lymphocytic leukemia

Cancer
Merat Karbasian-EsfahaniJanice P Dutcher

Abstract

Drug resistance and early disease recurrence were major contributing factors in the limited survival of patients with acute lymphocytic leukemia (ALL). New chemotherapeutic agents and drug combinations were employed in refractory patients to overcome drug resistance. The current study evaluated the efficacy of a regimen comprising intravenous bolus injections of idarubicin, 12 mg/m2 daily x 3, and a continuous 7-day infusion of cytosine arabinoside (ara-C), 100 mg/m2 daily, in adults with refractory or recurrent ALL. Twenty patients aged 14-75 years were treated. Six patients (30%) achieved complete remission (CR), 5 (25%) had a partial response (PR), and 9 (45%) did not respond. Recovery of blood counts occurred at a median of 20 days. One patient who achieved CR and one who achieved PR survived 1.5 and 2 years, respectively, after receiving this treatment. The median response and overall survival periods were 2.75 and 6.3 months, respectively. There was no relation between remission duration and previous chemotherapy. Neither leukocyte count at study entry nor patient karyotype was associated with attainment of CR. All patients experienced profound myelosuppression. Gastrointestinal toxicity was mild to moderate, with the exc...Continue Reading

References

May 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B D ChesonM J Keating
Jun 1, 1985·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M AbromowitchG Rivera
Jan 1, 1996·Leukemia & Lymphoma·J J MazzaP A Cassileth
Mar 15, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Francis J GilesHagop M Kantarjian
Jun 5, 2003·British Journal of Haematology·Maria Ilaria Del PrincipeSergio Amadori

❮ Previous
Next ❯

Citations

Oct 1, 2011·Current Treatment Options in Oncology·Peter H Wiernik
Feb 4, 2010·International Journal of Molecular Medicine·Andrew DavenportQ Ping Dou
Jul 12, 2008·Hematology·Merat Karbasian-EsfahaniLool Abebe
Nov 21, 2013·Leukemia & Lymphoma·Shira DinnerMichaela Liedtke
Nov 1, 2006·Expert Opinion on Drug Discovery·Janos Nadas, Duxin Sun
Aug 23, 2005·Cancer Chemotherapy and Biological Response Modifiers·Peter H Wiernik

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.